A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Palvella Therapeutics, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, 18 years or older (16 years or older in the UK)
Diagnosed with Pachyonychia Congenita (PC), genetically confirmed
You may not be if
Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications.
Any significant concurrent condition (including conditions involving or inferior to the ankle) that could adversely affect the patient's participation and/or the assessment of the safety and efficacy in the study.
Participation in any other interventional clinical research trial within 30 days prior to the screening visit or during the patient's participation in this study
Clareo Health | A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
